AbCellera Biologics (ABCL) Q4 2025 Earnings
How Did ABCL Stock React to Q4 2025 Earnings?
S&P 500 over the same 30 days: −8.52%.
Did ABCL Beat Earnings? Q4 2025 Results
Yes. AbCellera Biologics reported Q4 2025 earnings of $-0.03 a share on Feb 24, 2026, beating the $-0.18 consensus estimate by 83.3%. Revenue was $44.9M against a $6.7M estimate.
AbCellera Biologics delivered a sharp earnings beat in Q4 2025, with revenue of $44.90 million coming in well above the $6.71 million consensus estimate, a 569.55% positive surprise, as the quarter's results were driven primarily by an upfront payment from a patent litigation settlement. That single item propelled quarterly revenue 789.1% higher year over year and lifted full-year 2025 revenue to $75.13 million, compared to $28.83 million in 2024. On the bottom line, AbCellera posted a loss of $0.03 per share, beating the $0.18 consensus estimate by 83.33%, as the settlement proceeds sharply narrowed the quarterly net loss to $8.90 million. The strong print coincided with the company's transition to a clinical-stage biotech, having advanced ABCL635 into Phase 2 and ABCL575 into Phase 1 trials during the year; both programs are expected to deliver topline readouts in the second half of 2026. With roughly $700 million in total available liquidity, including non-dilutive government funding, AbCellera says it is funded well beyond three years, supporting continued pipeline investment and at least three anticipated IND submissions in 2027. Shares rose nearly 19% following the results.
- Upfront settlement payment from patent litigation drove Q4 2025 revenue of $44.9 million, representing 60% of full-year revenue
- Licensing and royalty revenue surged to $46.9 million from $1.0 million in FY 2024
- Completion of multi-year platform investments reduced capital expenditure requirements
“In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy.”
AbCellera Biologics CEO, on the earnings call
What Was AbCellera Biologics's Outlook in Q4 2025?
AbCellera's 2026 priorities include advancing ABCL635 and ABCL575 to topline Phase 1 clinical trial readouts in H2 2026, progressing ABCL688 and ABCL386 through IND-enabling studies, and nominating at least one additional development candidate for IND-enabling activities. The company anticipates multiple catalysts in 2027 including late-stage development of ABCL635 in menopausal VMS, initiation of Phase 2 studies of ABCL635 in oncology VMS, options for further development or out-licensing of ABCL575, and IND submissions with initiation of Phase 1/2 studies for ABCL688, ABCL386, and a new development candidate. The internal pipeline is expected to produce 1-2 development candidates per year. Available liquidity of approximately $700 million is expected to fund operations well beyond three years.
ABCL YoY Financials
| Metric | Q4 2025 | Q4 2024 | Year over year |
|---|---|---|---|
| Revenue | $44.9M | $5.0M | +789.1% |
| Net Income | −$8.9M | −$5.1M | +74.0% |
ABCL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.